Shitanshu Uppal
Korean HIPEC trial - IDS patients only 2023
HIPEC combined with ICS significantly improved PFS and OS in advanced-stage ovarian cancer patients, without increasing the rate of severe postoperative complications. A notable reduction in peritoneal recurrence may contribute to the OS improvement.
Publications Update # 78
Medicine is Difficult article, discussion of interlace trial and PRIMA final survival data
Korean HIPEC trial
The addition of HIPEC after interval cytoreductive surgery following neoadjuvant chemotherapy provided significant improvements in PFS and OS.
Interlace Trial
Induction chemotherapy followed by chemoradiotherapy significantly improves both progression-free survival and overall survival in patients with locally advanced cervical cancer compared to chemoradiotherapy alone.
Publications Update # 77
Living Room - Podcast Episode from Love+Radio, Keynote B21 trial and a video discussion of the trial and Compassion 16 trial in cervical cancer
COMPASSION 16
Cadonilimab potentially offers better PFS than pembrolizumab and atezolizumab therapies in recurrent advanced metastatic cervical cancer
Publications Update # 76
Focused Topic: Gestational Trophoblastic Neoplasia.
Gestational Trophoblastic Disease: Part 1
Publications Update # 75
Anthropocene Reviewed Podcast, tryanny of non-inferiority trials and a mini-tutorial on non-inferiority trials, GY-005 results, ENGOT-OV41 ANITA trial